تصفح حسب الموضوع "Ibrutinib"

السجلات المعروضة 1 -- 2 من 2

Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy

Onitilo, Adedayo A.; Piwuna, Tinuade O.; Islam, Nazmul; Furuya-Kanamori, Luis; Kumar, Sanjay; Doi, Suhail A.R.... more authors ... less authors ( Marshfield Clinic , 2022 , Article)
Objective: Within the last decade, the use of ibrutinib, a first-generation, non-selective, irreversible Burton's tyrosine kinase inhibitor for the treatment of hematological malignancies has proven highly effective in ...
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia Case report and literature review

Ghasoub, R; Albattah, A; Elazzazy, S; Alokka, R; Nemir, A; Alhijji, I; Taha, R... more authors ... less authors ( SAGE Publications Ltd , 2019 , Article)
Introduction: Ibrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used for a variety of B cell hematological malignancies. Skin and subcutaneous tissue manifestations have been reported and were witnessed ...